D. Boral Capital Reiterates "Buy" Rating for Avita Medical (NASDAQ:RCEL)

Key Points

• D. Boral Capital has reiterated a "Buy" rating for Avita Medical's stock (NASDAQ: RCEL) with a price target of $14.00, suggesting a potential upside of 160.22% from the last close.
• Other analysts have mixed views; Weiss Ratings recently issued a "sell" rating, while Lake Street Capital downgraded the stock from "buy" to "hold," indicating uncertainty in market sentiment.
• Avita Medical reported a loss of $0.38 per share in its latest earnings, missing estimates, with a negative net margin of 68.87%, highlighting ongoing financial challenges.

Avita Medical (NASDAQ:RCEL - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $14.00 price objective on the stock. D. Boral Capital's target price indicates a potential upside of 160.22% from the stock's previous close.

A number of other equities research analysts also recently weighed in on RCEL. Weiss Ratings reissued a "sell (d-)" rating on shares of Avita Medical in a report on Wednesday, October 8th. Wall Street Zen cut Avita Medical from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. BTIG Research cut Avita Medical from a "neutral" rating to a "sell" rating and set a $3.00 target price for the company. in a research report on Friday, August 8th. Finally, Lake Street Capital lowered Avita Medical from a "buy" rating to a "hold" rating in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Avita Medical currently has a consensus rating of "Hold" and an average target price of $11.60.

Avita Medical Price Performance

Shares of NASDAQ RCEL opened at $5.38 on Friday. Avita Medical has a 12 month low of $3.60 and a 12 month high of $14.16. The company has a 50-day simple moving average of $5.08 and a 200-day simple moving average of $6.18. The company has a market cap of $143.22 million, a PE ratio of -2.73 and a beta of 1.64.

Avita Medical (NASDAQ:RCEL - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.12). The business had revenue of $18.42 million for the quarter, compared to analyst estimates of $34.27 million. Avita Medical had a negative net margin of 68.87% and a negative return on equity of 632.62%. Avita Medical has set its FY 2025 guidance at EPS. On average, analysts anticipate that Avita Medical will post -0.95 EPS for the current year.

Insiders Place Their Bets

In other Avita Medical news, Director Robert Mcnamara purchased 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 28th. The shares were acquired at an average price of $4.50 per share, for a total transaction of $45,000.00. Following the purchase, the director owned 86,771 shares in the company, valued at approximately $390,469.50. The trade was a 13.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders acquired 24,000 shares of company stock valued at $113,660. 2.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC acquired a new position in Avita Medical in the 3rd quarter valued at $32,000. CWM LLC grew its holdings in shares of Avita Medical by 1,099.5% during the 1st quarter. CWM LLC now owns 4,918 shares of the company's stock worth $40,000 after purchasing an additional 4,508 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Avita Medical by 688.9% during the 1st quarter. GAMMA Investing LLC now owns 6,374 shares of the company's stock worth $52,000 after purchasing an additional 5,566 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Avita Medical during the 1st quarter worth $53,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Avita Medical during the 2nd quarter worth $58,000. 27.66% of the stock is owned by institutional investors and hedge funds.

About Avita Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.